cT84.66 

cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

cT84.66 binds bivalently and with high affinity (K_a=4.0 × 10¹⁰ M^-1) to CEA^[1].
cT84.66 (5-10 mCi ¹²³I per 1 mg cT84.66 minibody) can be efficiently radiolabeled with ¹²³I, yielding a product with ≥95% immunoreactivity, ≥90% radiolabeling efficiency, and endotoxin levels <1 unit/mL^[1].
cT84.66-DOTA has superior kinetic stability to cT84.66-DTPA when labeled with ¹¹¹In or ⁹⁰Y^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Radiolabeled cT84.66 minibody achieves tumor uptake up to 30% injected dose per gram in LS-174T colon cancer xenografts, with faster blood clearance than intact antibodies and superior tumor-to-blood ratios compared with cT84.66 F(ab')2 fragment^[1].
⁹⁰Y-DOTA-cT84.66 achieves high tumor uptake (approaching 60% ID/g) with low bone uptake (1%-2% ID/g) in tumor-bearing mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1048  [NCBI]

P06731

CEACAM5/CEA/CD66e

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wong JY, et al. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 2004;10(15):5014-5021.

  [2]. Wong JY, et al. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm. 2006;21(2):88-100.